Pantoprazol Biofarmoz (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Biofarmoz, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat acid‑related disorders such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults. GNH USA supplies Pantoprazol Biofarmoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Pantoprazol Biofarmoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Biofarmoz is a proton pump inhibitor that acts on the gastric acid secretion pathway.

- Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the esophageal lining. - Erosive oesophagitis: accelerates mucosal healing and reduces further erosion. - Peptic ulcer disease: supports ulcer healing and helps prevent recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the condition. - Helicobacter pylori eradication regimens: used as an adjunct to antibiotic therapy to improve eradication rates.

Pantoprazol Biofarmoz is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: typically self‑limiting. - Nausea: occasional and transient. - Abdominal pain: mild discomfort. - Flatulence: excess gas formation. - Constipation: infrequent.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: including rash, angioedema or anaphylaxis. - Clostridioides difficile infection: may present with severe diarrhea. - Acute interstitial nephritis: renal inflammation requiring medical attention. - Low magnesium levels (hypomagnesemia): can cause muscle cramps or cardiac arrhythmia. - Fracture risk: long‑term use may be associated with increased bone fracture incidence. - Liver enzyme elevations: abnormal hepatic function tests.

When prescribing Pantoprazol Biofarmoz, clinicians should consider several safety aspects.

- Renal impairment: dose adjustment may be required in severe kidney disease. - Hepatic impairment: use with caution in patients with liver dysfunction. - Long‑term therapy: monitor for potential bone density loss and magnesium levels. - Drug interactions: review concomitant medications for possible CYP‑mediated effects. - Pregnancy and lactation: assess risk‑benefit ratio before use. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Pantoprazol Biofarmoz can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Antifungal agents (ketoconazole, itraconazole): reduced absorption due to higher gastric pH. - HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma concentrations. - Clopidogrel: diminished antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR values. - Digoxin: altered absorption may require serum level monitoring. - Methotrexate: increased systemic exposure, especially at high doses.